AbbVie (ABBV) Interest & Investment Income (2012 - 2026)
AbbVie (ABBV) reported Interest & Investment Income of -$645.0 million for Q1 2026, down 2.87% year-over-year from -$664.1 million in Q1 2025, and up 1.53% quarter-over-quarter from -$655.0 million in Q4 2025.
AbbVie (ABBV) Interest & Investment Income (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Interest & Investment Income data on file, last reported at -$645.0 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at -$645.0 million, down 2.87% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.6 billion (down 13.32% YoY), and the FY2025 annual result was -$2.6 billion, down 21.62% from the prior year.
- Interest & Investment Income advanced to -$645.0 million in Q1 2026 per ABBV's latest filing, from -$655.0 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at -$378.0 million in Q4 2023 and troughed at -$678.0 million in Q2 2025.
- A 5-year average of -$538.8 million and a median of -$532.0 million in 2022 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2024: Interest & Investment Income gained 20.59% in 2023, then slumped 61.38% in 2024.
- A 5-year view of Interest & Investment Income shows it stood at -$476.0 million in 2022, then grew by 20.59% to -$378.0 million in 2023, then tumbled by 61.38% to -$610.0 million in 2024, then declined by 7.38% to -$655.0 million in 2025, then rose by 1.53% to -$645.0 million in 2026.
- Business Quant data shows ABBV's Interest & Investment Income at -$645.0 million in Q1 2026, -$655.0 million in Q4 2025, and -$667.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 29.66 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 229.00 Mn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -645.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -645.00 Mn |
| Dec 31, 2025 | -655.00 Mn |
| Sep 30, 2025 | -667.00 Mn |
| Jun 30, 2025 | -678.00 Mn |
| Mar 31, 2025 | -627.00 Mn |
| Dec 31, 2024 | -610.00 Mn |
| Sep 30, 2024 | -591.00 Mn |
| Jun 30, 2024 | -506.00 Mn |
| Mar 31, 2024 | -453.00 Mn |
| Dec 31, 2023 | -378.00 Mn |
| Sep 30, 2023 | -398.00 Mn |
| Jun 30, 2023 | -454.00 Mn |
| Mar 31, 2023 | -454.00 Mn |
| Dec 31, 2022 | -476.00 Mn |
| Sep 30, 2022 | -497.00 Mn |
| Jun 30, 2022 | -532.00 Mn |
| Mar 31, 2022 | -539.00 Mn |
| Dec 31, 2021 | -571.00 Mn |
| Sep 30, 2021 | -585.00 Mn |
| Jun 30, 2021 | -606.00 Mn |